|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
multiple countries
|
|
gptkbp:approves
|
gptkb:U._S._Food_and_Drug_Administration
December 18, 2020
|
|
gptkbp:average_temperature
|
-20 degrees Celsius
|
|
gptkbp:brand
|
gptkb:Spikevax
|
|
gptkbp:clinical_trial
|
over 30,000
Phase 3
multiple sites worldwide
|
|
gptkbp:clinical_trial_results_published
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:collaboration
|
increased
|
|
gptkbp:community_health
|
gptkb:significant
|
|
gptkbp:developed_by
|
Moderna, Inc.
|
|
gptkbp:distribution
|
over 70 countries
|
|
gptkbp:dosage_form
|
yes
two doses
|
|
gptkbp:emergency_services
|
yes
|
|
gptkbp:funding
|
gptkb:U._S._government
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Moderna's COVID-19 vaccine
|
|
gptkbp:is_effective_against
|
94.1%
|
|
gptkbp:is_vulnerable_to
|
gptkb:logistics
gptkb:complex
global
ongoing
important
improved
expanded
philanthropic organizations
lipid nanoparticle
viral vector vaccine
against severe disease
against hospitalization
against symptomatic infection
m RNA technology
|
|
gptkbp:manufacturer
|
Moderna, Inc.
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:partnerships
|
various governments
|
|
gptkbp:production_volume
|
billions of doses
|
|
gptkbp:public_awareness
|
implemented
|
|
gptkbp:route_of_administration
|
intramuscular injection
|
|
gptkbp:safety_measures
|
active
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
fever
joint pain
rare allergic reactions
|
|
gptkbp:storage_duration
|
up to 30 days in refrigerator
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:vaccine_approval_process
|
expedited
|
|
gptkbp:vaccine_clinical_data
|
extensive
|
|
gptkbp:vaccine_development_speed
|
rapid
|
|
gptkbp:vaccine_distribution_network
|
established
|
|
gptkbp:vaccine_distribution_partnerships
|
pharmaceutical companies
|
|
gptkbp:vaccine_effectiveness_studies
|
conducted
|
|
gptkbp:vaccine_equity_efforts
|
prioritized
|
|
gptkbp:vaccine_impact_assessment
|
ongoing
|
|
gptkbp:vaccine_public_health_guidelines
|
followed
|
|
gptkbp:vaccine_public_trust
|
critical
|
|
gptkbp:vaccine_updates
|
frequent
|
|
gptkbp:bfsParent
|
gptkb:Lonza_Group
|
|
gptkbp:bfsLayer
|
6
|